Prediction Methods for Nicotine Clearance Using Cotinine and 3-Hydroxy-Cotinine Spot Saliva Samples II. Model Application
- 6 January 2007
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 34 (1) , 23-34
- https://doi.org/10.1007/s10928-006-9026-0
Abstract
To develop and compare methods that predict individual nicotine (NIC) clearance, which reflects CYP2A6 activity, using random saliva cotinine (COT) and trans 3′-hydroxycotinine (3HC) measurements. COT and 3HC saliva concentrations in smokers were simulated utilizing a mechanistic population pharmacokinetic model of NIC metabolism that was adapted from the one described in a companion paper. Four methods to predict NIC clearance using the metabolites concentrations were compared. The precision bias, and the fraction of predictions that are made with an absolute error below 25% were the performance measures evaluated. Four prediction methods were compared: (M1) reference method, an intercept slope model of the metabolite concentration ratios ([3HC]/[COT]) (M2) an intercept slope model of the natural logarithm of the metabolite ratios (M3) a spline of the logarithm of the metabolite ratios (M4) Maximal Posteriori Bayesian estimate of NIC clearance conditioned on the model, COT and 3HC concentrations. In addition, the effect of smoking patterns on the concentrations of COT and 3HC was evaluated. The precision, accuracy, and the fraction of predictions with an absolute error below 25%, were higher for methods M2–M4 compared to method M1. However, the differences between M2 and M4 were small. Additionally, smoking pattern did not affect the metabolite concentration profiles. Predicting NIC clearance using an intercept slope model of the natural logarithm of the ratio of 3HC to COT appears to be a relatively simple method that is better than using the metabolite ratio directly. This method has a bias of approximately −10%, precision of approximately 60%. The fraction of estimates below an absolute error of 25% is 43%. These results support use of M2 to estimate CYP2A6 activity in smokers in the clinical setting.Keywords
This publication has 15 references indexed in Scilit:
- Population Pharmacokinetics of Nicotine and Its Metabolites I. Model DevelopmentJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Metabolism and Disposition Kinetics of NicotinePharmacological Reviews, 2005
- Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influencePharmacogenetics and Genomics, 2005
- Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1Clinical Pharmacology & Therapeutics, 2004
- An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 AllelesBiochemical and Biophysical Research Communications, 2002
- Cotinine as a Biomarker of Environmental Tobacco Smoke ExposureEpidemiologic Reviews, 1996
- Controlling Correlations in Latin Hypercube SamplesJournal of the American Statistical Association, 1994
- Large Sample Properties of Simulations Using Latin Hypercube SamplingTechnometrics, 1987
- Cotinine disposition and effectsClinical Pharmacology & Therapeutics, 1983
- Forecasting individual pharmacokineticsClinical Pharmacology & Therapeutics, 1979